DEXILANT DIN 02354950
Health Canada record
| Active ingredient(s) | DEXLANSOPRAZOLE 30 MG |
|---|---|
| Dosage form | Capsule (Delayed-Release) |
| Route | Oral; Nasogastric |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A02BC06 DEXLANSOPRAZOLE |
| Original market date | 05-Aug-2010 |
| Current status date | 13-Jan-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Takeda Canada Inc. — licence 101769, currently licensed, last inspection rating C (2026-02-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DEXLANSOPRAZOLE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02528991 | APO-DEXLANSOPRAZOLE | APOTEX INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 30 MG | Marketed |
| 02529025 | APO-DEXLANSOPRAZOLE | APOTEX INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 60 MG | Marketed |
| 02354969 | DEXILANT | TAKEDA CANADA INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 60 MG | Marketed |
| 02523361 | DEXLANSOPRAZOLE | TAKEDA CANADA INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 60 MG | Cancelled Pre Market |
| 02536404 | DEXLANSOPRAZOLE | ALTIUS HEALTHCARE INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 60 MG | Cancelled Post Market |
| 02536390 | DEXLANSOPRAZOLE | ALTIUS HEALTHCARE INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 30 MG | Cancelled Post Market |
| 02523353 | DEXLANSOPRAZOLE | TAKEDA CANADA INC | Capsule (Delayed-Release) | DEXLANSOPRAZOLE 30 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 18777 | 2016-12-16 | Supplement to a New Drug Submission (SNDS) | UPDATE TO THE LALBELLING OF THE SAFETY INFORMATION WITH RESPECT TO INTERACTION WITH ANTIRETROVIRAL PRODUCTS |
| 11609 | 2010-07-22 | New Drug Submission (NDS) |
International API supply for DEXLANSOPRAZOLE
23 active FDA Drug Master Files.
Request a quote for DEXILANT